World ADC
Harnessing the promise of empowered antibodies
26 - 28 February 2013
Frankfurt
Antibody drug conjugate experts descended on Frankfurt recently as the European community convened for its annual Summit. At the top of the agenda were issues surrounding European regulation, ADC characterisation & process development and drug safety & PK.
Through dedicated networking sessions and informative presentations, stakeholders new and old refined how they can develop and implement a successful ADC program.
“The ADC Summit is very informative for people who are new to this field as well as the ADC experts. All of the talks were excellent”. Bristol-Myers Squibb
Highlights of the World ADC Summit Europe included:
This year's meeting has now run. Please email: info@hansonwade.com if you'd like more information about the 2013 meeting.
John Lambert, Executive Vice President & Chief Scientific Officer, ImmunoGen
Paul Polakis, Director, Cancer Targets, Genentech
Hans Peter Gerber, Senior Director, Bioconjugates and Vascular Biology, Pfizer
Sanjeev Gangwar, Senior Director, Medicinal Chemistry, Bristol-Myers Squibb
Dennis Benjamin, Senior Director, Experimental Therapies, Seattle Genetics
Peter Senter, Vice President, Chemistry, Seattle Genetics
Alain Beck, Head of Physico-Chemistry Department, Pierre Fabre
“Excellent and detailed overview of the state of the art in ADC discovery. I would definitely come back for a second round. Nice job organising the event." Pfizer
“It was great opportunity to join ADC community and get the latest information. Thanks!" Daiichi Sankyo
“THE best opportunity to meet the pioneers in the field of ADC." AstraZeneca
“The conference was fantastic. The group in general and presenters in particular were very open to new technologies and ideas.” Alvos Therapeutics